http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. Human osteosarcoma samples are hard to come by, making the disease difficult to study. However, K9 bone cancer is genetically indistinguishable from the human form of the disease, and over 10,000 canine patients develop the disease every year. Research from the University of Colorado Cancer Center and the Colorado State University Flint Animal Cancer Center presented at the AACR Annual Meeting 2013 used easily available K9 osteosarcoma samples to discover a novel protein that governs metastasis and chemoresistance in pediatric osteosarcoma. http://medicalxpress.com/news/2013-04-k9-osteosarcoma-samples-drivers-metastasis.html Cancer Tue, 09 Apr 2013 09:42:26 EST news284719337 Preclinical, laboratory studies suggest a novel immunotherapy could potentially work like a vaccine against metastatic cancers, according to scientists at Virginia Commonwealth University Massey Cancer Center. Results from a recent study show the therapy could treat metastatic cancers and be used in combination with current cancer therapies while helping to prevent the development of new metastatic tumors and train specialized immune system cells to guard against cancer relapse. http://medicalxpress.com/news/2013-02-cancer-vaccine-future-metastatic-cancers.html Cancer Wed, 27 Feb 2013 10:39:47 EST news281183979 New research in animals triggered by a combination of serendipity and counterintuitive thinking could point the way to treating fractures caused by rapid bone loss in people, including patients with metastatic cancers. http://medicalxpress.com/news/2013-02-steroids-reverse-rapid-bone-loss.html Medical research Tue, 05 Feb 2013 17:00:01 EST news279305366 Scientists from the University of Iowa and Brigham Young University (BYU) have identified a gene that may be a target for overcoming drug resistance in cancer. The finding could not only improve prognostic and diagnostic tools for evaluating cancer and monitoring patients' response to treatment but also could lead to new therapies directed at eradicating drug-resistant cancer cells. http://medicalxpress.com/news/2013-01-team-gene-drug-resistance-cancer.html Cancer Mon, 14 Jan 2013 12:00:01 EST news277386993 (Medical Xpress)—Researchers from Roswell Park Cancer Institute (RPCI) have published findings from a preclinical study assessing the effectiveness of a small-molecule inhibitor, CFAK-Y15, in treating some brain cancers. The paper, published in Molecular Cancer Therapeutics, demonstrates for the first time that inhibiting the protein focal adhesion kinase (FAK) with CFAK-Y15 is an effective approach to controlling growth of glioblastoma tumors, especially in combination with the standard chemotherapy agent temozolomide (Temodar). http://medicalxpress.com/news/2012-12-fak-inhibitor-effective-brain-tumors.html Cancer Mon, 24 Dec 2012 07:40:26 EST news275557166 Patient-reported outcomes should be a standard part of evaluating the comparative effectiveness of cancer treatments, according to recommendations put forward by a multi-institution research group. http://medicalxpress.com/news/2012-10-patient-reported-outcomes-essential-effectiveness.html Cancer Tue, 16 Oct 2012 13:41:44 EST news269613691 A potentially powerful new approach to treating two lethal metastatic cancers — triple negative breast cancer and clear cell renal cell carcinoma, the most common form of kidney cancer — has been discovered by researchers at Mayo Clinic in Florida. In the online issue of Molecular Cancer Therapeutics, they report that two drugs, romidepsin and decitabine, work cooperatively to activate a potent tumor suppressor gene that is silenced in these cancers. Once the gene, secreted frizzled related protein one or sFRP1, went to work after the drugs were used, the laboratory tumor cells stopped growing and died. http://medicalxpress.com/news/2012-07-drug-duo-cancer-fighting-gene-kidney.html Cancer Tue, 31 Jul 2012 15:27:07 EST news262967220 (Medical Xpress) -- Investigators have identified a new class of human immune cells that behave like stem cells. These cells, a subtype of T lymphocytes, which comprise a small fraction of white blood cells, may prove more effective than any previously reported type of T cell for treating tumors. The study, by scientists at the National Cancer Institute (NCI), part of the National Institute of Health, describes how these stem cell-like T cells can trigger a prolonged immune attack against tumor cells by continuously generating killer T cells and regenerating themselves. The findings were published online Sept. 18, 2011, in Nature Medicine. http://medicalxpress.com/news/2011-09-scientists-approach-prolong-immune-tumor.html Cancer Wed, 21 Sep 2011 07:33:46 EST news235809166